HX575 epoetin alfa (Sandoz)

Phase 3

Sandoz Group AG (SDZ.SW)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

4 competitors in Chronic Kidney Disease

SNYSevelamer hydrochloride

Drug Information

Target Indication

Chronic Kidney Disease

Clinical Trial

NCT01576341

Last updated: 6/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

SDZ.SW

Sandoz Group AG

Pharmaceutical Preparations•Europe•SIX

Related Pipeline

Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)Phase 3

Rhinitis, Allergic, Seasonal

HX575, solution for injection (s.c.)Phase 3

Anemia

GP2015 EtanerceptPhase 3

Chronic Stable Plaque Psoriasis

GP2013Phase 3

Follicular Lymphoma

SOK583A1 (40 mg/mL)Phase 3

Neovascular Age-related Macular Degeneration

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts